Cingulate Inc , a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder.
infoCingulate is a micro cap stock with a total market cap of 10.41M.
infoThey trade on the NASDAQ and had their IPO 1 year and 8 months ago.
infoCingulate currently employs 15 people.
infoAs of Wednesday, Aug 23 2023, Cingulate’s share price is $0.6646.
News Relating to Cingulate
GlobeNewsWire
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
Wednesday Jun 14 2023 at 15:45
KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, Pharm D, has been invited to participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest. The three-day conference will kick off Tuesday, June 20th at 9:00 AM EST, and conclude on Thursday, June 22nd.
GlobeNewsWire
Cingulate to Present at 13th Annual LD Micro Invitational
Thursday May 25 2023 at 15:55
KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.
PennyStocks
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch
Friday Mar 10 2023 at 13:20
Short squeeze penny stocks to watch. The post Best Penny Stocks To Buy?
PennyStocks
Building a Penny Stocks Portfolio For Long Term
Monday Feb 27 2023 at 06:00
Use these tips for buying penny stocks for the long term The post Building a Penny Stocks Portfolio For Long Term appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
The Psychology of Penny Stock Trading: Tips for Emotional Control
Saturday Feb 25 2023 at 11:00
Tips for making money with penny stocks The post The Psychology of Penny Stock Trading: Tips for Emotional Control appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
InvestorPlace
Why Is Cingulate (CING) Stock Up 72% Today?
Friday Feb 24 2023 at 07:47
Cingulate (NASDAQ: CING ) stock is on the rise Friday after releasing positive data concerning its ADHD treatment. The big news today is Cingulate’s CTx-1301 can be taken with or without food.
Market Watch
Cingulate stock skyrockets after ADHD treatment shows positive trial results
Friday Feb 24 2023 at 07:04
Shares of Cingulate Inc. CING, +2.78% skyrocketed 82.9% toward an 11-month high in active premarket trading Friday, after the biopharmaceutical company reported positive results from a trial of its attention deficit/hyperactivity disorder (ADHD) treatment. With trading volume spiking to over 3.2 million shares, compared with the full-day average of about 112,400 shares, the stock was the biggest gainer and most active listed on major U.S. exchanges.
Newsfile Corp
Cingulate Inc. to Present at Investor Summit Group’s Q4 Conference
Thursday Nov 03 2022 at 07:00
Kansas City, Kansas–(Newsfile Corp. – November 3, 2022) – Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Shane Schaffer, CEO, and Tom Dalton, Vice President of IR & PR, will present a company overview at the Q4 Investor Summit live in New York City at the Sheraton Times Square.
GlobeNewsWire
Cingulate to Present at LD Micro Investor Conference
Thursday Oct 20 2022 at 14:20
KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022.
GlobeNewsWire
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational
Friday Jun 17 2022 at 12:45
KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on Thursday, June 23, 2022 at 1:40 PM EST. Following the presentation, Dr. Schaffer will take questions from participants.
GlobeNewsWire
Cingulate to Present at H.C. Wainwright Global Investment Conference
Wednesday May 18 2022 at 17:20
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, and Chief Medical Officer, Matthew Brams, M.D., will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, from 3:00-3:30 p.m. ET, at the Fontainebleau Miami Beach Hotel, Miami, FL.
Benzinga
Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies
Tuesday Feb 08 2022 at 12:20
Cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) in 2022. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
Cingulate Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Cingulate’s Altman Z-score is -31.6 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Cingulate Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $1.00M of common stock in Cingulate on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Cingulate’s Current Ratio of 0.19 is lower than its Industry Group of 4.76 (-96.0% lower)
Cingulate’s Current Ratio of 0.19 is lower than its Major Industry Group of 4.32 (-95.6% lower)
Cingulate’s Current Ratio of 0.19 is lower than its Sector of 2.6 (-92.7% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cingulate’s ROE of 1.11 is greater than its Industry Group of -0.44 (352.3% greater)
Cingulate’s ROE of 1.11 is greater than its Major Industry Group of -0.38 (392.1% greater)
Cingulate’s ROE of 1.11 is greater than its Sector of -0.03 (3800.0% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cingulate’s ROCE of 2.21 is greater than its Industry Group of -0.42 (626.2% greater)
Cingulate’s ROCE of 2.21 is greater than its Major Industry Group of -0.37 (697.3% greater)
Cingulate’s ROCE of 2.21 is greater than its Sector of -0.04 (5625.0% greater)
Derived from SEC.GOV filing dataopen_in_new